Trial success boosts Allergy
Allergy Therapeutics soared by a third Wednesday after the hay fever treatment group said phase III trials revealed Pollinex Quattro has statistically significant clinical benefits over a placebo.
"This is a landmark study and the most important news in the seventy year history of our company," said chief executive Keith Carter.
"This product has the potential to redefine the market for allergy products, offering sufferers a safe and effective therapy with a much more convenient treatment regime than is currently available."
(Article continues below)Advertisement
The results will be used to support a Marketing Approval Application in the European Union with a submission planned for the first quarter of 2009, said the firm.
"This high level of compliance demonstrates the clear advantages of Pollinex Quattro as a four injection therapeutic vaccine, offering same season relief in as little as three weeks after treatment," it added.
"Current therapeutic options are mostly limited to symptomatic therapies and/or conventional allergen immunotherapy which can require up to 90 injections in over three to five years."
